Search PubMed⌕ Search

Biomedical subjects

Marvin Moser

Publications and source records attributed to Marvin Moser.

At least 37 records · Page 2Linked to original sources
PubMed2005

Secondary hypertension--whom and how do you study? What type of therapy is appropriate?

Following a hypertension symposium in Los Angeles, CA on October 20, 2004, a roundtable was convened to discuss secondary or treatable forms of high blood pressure, when and whom should be studied, and treatment methods. Dr. Marvin Moser, Clinical Professor of Medicine at Yale University School of Medicine, New Haven, CT, moderated the panel discussion. Participants included Dr. Ron Victor, from the Southwestern Medical Center, Dallas, TX and Dr. Joel Handler of the Orange County Kaiser Permanente Hypertension Clinic, Anaheim, CA.

Antihypertensive Agents↗
PubMed2005

Roundtable discussion: the role of Beta blockers in the management of hypertension.

Following a hypertension symposium in New York City on February 2, 2005, a roundtable was convened to discuss the use of beta blockers in the management of hypertension. Dr. Marvin Moser, Clinical Professor of Medicine at the Yale University School of Medicine, New Haven, CT, moderated the discussion. Participating in this roundtable were Dr. Thomas Pickering, Professor of Medicine at the Columbia University School of Medicine, New York, NY, and Dr. William Cushman, Professor of Preventive Medicine and Medicine at the University of Tennessee College of Medicine, Memphis, TN.

Adrenergic beta-Antagonists↗
PubMed2005

Conflicting and confusing data from the hypertension treatment trials: whom and what should you believe?

Following a hypertension symposium in Atlanta, GA on March 30, 2005, a roundtable was convened to discuss a confusing topic: "Conflicting Information from the Hypertension Treatment Trials: Whom and What Should You Believe?" Dr. Marvin Moser, Clinical Professor of Medicine at the Yale University School of Medicine, New Haven, CT, moderated the panel discussion. Participants included Dr. Thomas Giles, Professor of Medicine at Louisiana State University Health Sciences Center, New Orleans, LA and President of the American Society of Hypertension, and Dr. Suzanne Oparil, Professor of Medicine at the University of Alabama at Birmingham, Birmingham, AL.

Blood Pressure↗
PubMed2005

Hypertension, renal disease, and cardiovascular outcomes.

During the meeting of the American Society of Hypertension in San Francisco, CA on May 17, 2005, a roundtable was convened to discuss the relationship between hypertension, renal disease, and cardiovascular outcomes. Dr. Marvin Moser, Clinical Professor at Yale University School of Medicine, New Haven, CT, chaired the session. Dr. Jan Basile, Professor of Medicine at the Ralph Johnson VA Medical Center and the Medical University of South Carolina in Charleston, SC and Dr. William Cushman, Professor of Preventive Medicine and Medicine at the University of Tennessee in Memphis, TN participated in the discussion.

Albuminuria↗
PubMed2005

A conversation with Drs. Kaplan and Moser about conflicting data, confusing results, and some recent treatment recommendations for the management of hypertension.

Following a hypertension symposium in Baltimore, MD, on June 1, 2005, Dr. Wendy Post from the Johns Hopkins University School of Medicine, Baltimore, MD, had the opportunity to interview two of the outstanding hypertension experts in the United States on several controversial issues in hypertension management. Dr. Norman Kaplan is Clinical Professor of Medicine at the Southwestern Health Science Center in Dallas, TX, and Dr. Marvin Moser is Clinical Professor of Medicine at the Yale University School of Medicine, New Haven, CT. Both have been leaders in the field of hypertension treatment and education for more than 40 years. Dr. Kaplan's book Clinical Hypertension has been a standard textbook since 1973 and is now in its ninth edition. Dr. Marvin Moser was the Senior Medical Consultant to the National High Blood Pressure Education Program from 1974 to 2002 and was Chairman of the first Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure and a member of the six subsequent committees. His book Clinical Management of Hypertension is in its seventh edition. Drs. Moser and Kaplan were corecipients of the 2004 International Society of Hypertension Award for Outstanding Contributions to Hypertension Treatment and Education and have lectured extensively throughout the United States and overseas.

Angiotensin II Type 1 Receptor Blockers↗
PubMed2005

The ASCOT trial.

Explore the source record for details and available documents.

Antihypertensive Agents↗
PubMed2005

Roundtable discussion: hypertension in children and adolescents.

Following a hypertension symposium held in Philadelphia, PA, on June 8, 2004, a roundtable discussion was held to discuss the treatment of hypertension in adolescents and children. The participants included Thomas D. Giles, MD, of Louisiana State College of Medicine, New Orleans, LA; Bonita Falkner, MD, of the Department of Medicine and Pediatrics, Thomas Jefferson University, Philadelphia, PA; Allan B. Schwartz, MD, of the Division of Nephrology and Hypertension, Drexel University College of Medicine, Philadelphia, PA; Raymond R. Townsend, MD, of the Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA; and Marvin Moser, MD, of the Department of Medicine/Cardiology, Yale University School of Medicine, New Haven, CT.

Adolescent↗
PubMed2004

Continued importance of diuretics and beta-adrenergic blockers in the management of hypertension.

The use of thiazide diuretics as one of the preferred antihypertensive medications has stood the test of time. Since the introduction of orally effective agents in 1957 to 1958, these drugs have continued to prove their usefulness. Numerous clinical trials have confirmed that these medications are as or more effective in reducing blood pressure and cardiovascular events than any of the other effective antihypertensive agents. Although some metabolic changes may occur with higher dosages of these medications, they seem to be of limited clinical significance. In addition to being well tolerated and effective. thiazide-type diuretics are less expensive than other agents. This should be considered in view of the fact that quality of care is not compromised when the less expensive medication is used. beta-Blockers should also be considered as a major drug class in the management of hypertensive patients. There are few studies directly comparing these drugs with other agents. Although some data suggest that they are less effective in reducing CHD events in the elderly, there are numerous situations where beta-blockers are clearly indicated. Combination therapy with a beta-blocker and diuretic has been shown to be highly effective in reducing cardiovascular events in both diabetic and nondiabetic patients.

Adrenergic beta-Antagonists↗